133 related articles for article (PubMed ID: 18600575)
1. Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic.
Day M; Balci F; Wan HI; Fox GB; Rutkowski JL; Feuerstein G
Curr Opin Investig Drugs; 2008 Jul; 9(7):696-706. PubMed ID: 18600575
[TBL] [Abstract][Full Text] [Related]
2. Developing drugs for cognitive impairment in schizophrenia.
Breier A
Schizophr Bull; 2005 Oct; 31(4):816-22. PubMed ID: 16150959
[TBL] [Abstract][Full Text] [Related]
3. Animal models of cognitive function.
Decker MW
Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
[TBL] [Abstract][Full Text] [Related]
4. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
5. [Learning potential and cognitive remediation in schizophrenia].
Raffard S; Gely-Nargeot MC; Capdevielle D; Bayard S; Boulenger JP
Encephale; 2009 Sep; 35(4):353-60. PubMed ID: 19748372
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Nuechterlein KH; Robbins TW; Einat H
Schizophr Bull; 2005 Oct; 31(4):870-4. PubMed ID: 16150960
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
8. Preclinical research into cognition enhancers.
Sarter M
Trends Pharmacol Sci; 2006 Nov; 27(11):602-8. PubMed ID: 16997388
[TBL] [Abstract][Full Text] [Related]
9. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
10. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
Floresco SB; Geyer MA; Gold LH; Grace AA
Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment--proof of concept.
Rolstad S; Nordlund A; Eckerström C; Gustavsson MH; Zetterberg H; Wallin A
Dement Geriatr Cogn Disord; 2009; 27(2):194-200. PubMed ID: 19225233
[TBL] [Abstract][Full Text] [Related]
12. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
Severino ME; Dubose RF; Patterson SD
IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
[TBL] [Abstract][Full Text] [Related]
13. Psychopharmacological strategies in the search for cognition enhancers.
Sanger DJ; Joly D
Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():70-4. PubMed ID: 2186417
[TBL] [Abstract][Full Text] [Related]
14. [Usage of drugs with potential adverse effects on cognition in a memory-clinic].
Weih M; Scholz S; Reiss K; Alexopoulos P; Degirmenci U; Richter-Schmidinger T; Kornhuber J
Fortschr Neurol Psychiatr; 2009 Sep; 77(9):523-7. PubMed ID: 19644785
[TBL] [Abstract][Full Text] [Related]
15. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
16. Early clinical testing of cognition enhancers: prediction of efficacy.
Hall ST; Puech A; Schaffler K; Wesnes K; Gamzu ER
Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():57-8; discussion 59. PubMed ID: 2186414
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the affective and cognitive effects of a drug: theoretical and methodological considerations.
Jouvent R
Arch Gerontol Geriatr Suppl; 1989; 1():165-72. PubMed ID: 2667541
[TBL] [Abstract][Full Text] [Related]
18. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
[TBL] [Abstract][Full Text] [Related]
19. Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease.
Takeda S; Sato N; Niisato K; Takeuchi D; Kurinami H; Shinohara M; Rakugi H; Kano M; Morishita R
Brain Res; 2009 Jul; 1280():137-47. PubMed ID: 19464276
[TBL] [Abstract][Full Text] [Related]
20. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG
J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
